Filing Details

Accession Number:
0001179110-20-001525
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-12 17:29:06
Reporting Period:
2020-02-10
Accepted Time:
2020-02-12 17:29:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA Biological Products, (No Disgnostic Substances) (2836) 043561634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1755174 Ann Jo Beltramello C/O Momenta Pharmaceuticals, Inc.
301 Binney St,
Cambridge MA 02142
Chief Hr And Inf. Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Commonstock Acquisiton 2020-02-10 2,363 $10.83 45,913 No 4 M Direct
Common Stock Acquisiton 2020-02-11 25,000 $12.76 70,913 No 4 M Direct
Common Stock Disposition 2020-02-10 2,363 $31.00 68,550 No 4 S Direct
Common Stock Disposition 2020-02-11 25,000 $31.49 43,550 No 4 S Direct
Common Stock Disposition 2020-02-11 528 $32.23 43,022 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2020-02-10 2,363 $0.00 2,363 $10.83
Common Stock Stock Option (Right to Buy) Acquisiton 2020-02-11 25,000 $0.00 25,000 $12.76
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,480 2019-08-09 2026-02-09 No 4 M Direct
57,053 2020-02-11 2029-02-11 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  2. This transaction was executed in multiple trades at prices ranging from $31.25 to $32.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.